Dec. 22 at 1:33 PM
$ADTX Like this one too at 2m mkt cap
Pearsanta’s Path Toward IPO
Pearsanta, a majority-owned subsidiary focused on early cancer detection tests, is progressing toward a planned IPO, which could unlock standalone valuation and potentially lead to capital inflows or strategic monetization upside for ADTX
New Strategic Framework (“bitXbio™”)
Aditxt unveiled its bitXbio™ strategy, combining biotech innovation with broader capital access initiatives (including a Bitcoin-backed treasury concept), aimed at enhancing liquidity and supporting future growth execution. This shows proactive thinking around funding sources and long-term expansion.
Continued Strategic Collaborations
Even after the termination of the Evofem merger, Aditxt and Evofem continue collaborating on commercialization of diagnostic products, maintaining relationships that could lead to future milestones or revenues
$KOD $PHAT $KSS
